Tag: clinical trial
tiakis Biotech Successfully Completes Data Package to Advance Tiprelestat into Phase II clinical trial in PAH
— 6-month GLP-tox study reinforces favorable safety profile of Tiprelestat
— Phase II Study in Pulmonary Arterial Hypertension (PAH) to be initiated by Stanford University in mid-2026
tiakis Biotech AG (“tiakis”), a clinical-stage biopharmaceutical company developing novel therapeutics for life-threatening pulmonary and cardiovascular diseases, today announced that the Company has successfully finalized a comprehensive data package to advance Tiprelestat into a Phase II clinical trial in Pulmonary Arterial Hypertension (PAH) by completing a preclinical GLP-tox study.
Thermosome Reports Encouraging Clinical Data of THE001 in Advanced Soft Tissue Sarcomas
— Heat-triggered release mechanism unequivocally confirmed
— Favorable safety profile with good tolerability
— Signs of encouraging clinical activity in heavily pre-treated patients including meaningful progression-free survival (PFS)
— One participant with previously unresectable disease in DL2 underwent surgery, indicating no vital tumor cells in the target lesion
Munich, Germany – June 24, 2025 – Thermosome GmbH, a clinical-stage drug development company focused on targeted tumor therapies, today announced new, encouraging data from its ongoing Phase I clinical trial evaluating its lead compound THE001 (DPPG2-TSL-DOX) in combination with regional hyperthermia (RHT) for the treatment of soft tissue sarcomas (STS). Read more…
Ebenbuild Contributes Cutting-Edge Digital Lung Simulations to Pulmonary Fibrosis Drug Development
— First-ever use of Ebenbuild’s Twinhale technology in idiopathic pulmonary fibrosis lung models
— Trial results published in Nature Communications
Ebenbuild, a company developing personalized, AI-enabled digital twins of lungs to support clinical decisions and digital clinical trials, today announced its contribution to a pioneering study published today in Nature Communications. The article titled Preclinical concept studies showing advantage of an inhaled anti-CTGF/CCN2 protein for pulmonary fibrosis treatment(DOI:10.1038/s41467-025-58568-x) highlights the potential of inhaled therapeutics for treating idiopathic pulmonary fibrosis (IPF), a devastating lung disease with limited treatment options. Read more…
New Clinical Data on BellaSeno’s Novel, Resorbable Breast Implants Presented at The Aesthetic MEET 2025
— Presentation by Prof. Anand Deva highlights 87% breast volume retention and low complication rate in one-year patient follow-up
— Successful vascularization and vessel formation in two-year follow-up
— 3D-printed resorbable scaffold to preserve both volume and shape of autologous fat in the medium to long term
BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, today announced that Prof. Anand Deva presented new clinical data on BellaSeno’s novel, 3D-printed, resorbable breast scaffolds at The Aesthetic MEET 2025 conference in Austin, TX, USA.